Giuseppe Banna: 177Lu-PSMA-617 for metastatic prostate cancer in LMICs
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on LinkedIn:
“In this paper, we explore the practical challenges, opportunities, and future directives for radioligand therapy with 177Lu-PSMA-617 for treating metastatic prostate cancer in low- and middle-income countries (LMICs). With a growing need for cost-effective cancer treatments, this research highlights the potential impact of indigenous production and improved access to advanced therapies.
Thanks to the entire team for their collaboration on this important work!”
177Lu-PSMA-617 for metastatic prostate cancer in India
Authors: Aruni Ghose, Soirindhri Banerjee, Partha S. Choudhury, Akash Maniam, Manoj Gupta, Giuseppe L. Banna, Nikhil Vasdev, Amit Ghose, Vanita Noronha, Swarupa Mitra
Source: Giuseppe Banna/LinkedIn
Giuseppe Banna is a Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust and the Candiolo Cancer Institute IRCCS. He leads the Translational Research and Clinical Trials Unit for Thoracic Tumors. Additionally, he serves as an Honorary Teacher Practitioner at the Universities of Nottingham and Lincoln, and is affiliated with United Lincolnshire Hospitals NHS Trust.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023